OC
LEGN icon

Oppenheimer & Co’s Legend Biotech LEGN Stock Holding History

Oppenheimer & Co’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Sell
21,486
-5,364
-20% -$145K 0.01% 1157
2026
Q1 		$486K Buy
+26,850
New +$512K 0.01% 1199

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Oppenheimer & Co's LEGN Position: Q2 2026 in Review

Oppenheimer & Co reduced its Legend Biotech (LEGN) stake by 20% in Q2 2026, selling an estimated $145K and leaving 21,486 shares worth $621K. The position accounts for 0.01% of the portfolio, ranked #1157.

Oppenheimer & Co first reported a position in LEGN in Q1 2026 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Oppenheimer & Co held 21,486 shares of Legend Biotech worth $621K as of Q2 2026.
  • Oppenheimer & Co sold 5,364 Legend Biotech shares in Q2 2026, an estimated $145K.
  • Legend Biotech made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1157 holding.
  • Oppenheimer & Co first reported a position in Legend Biotech in Q1 2026 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.